Search company, investor...
Search
Nutcracker Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

nutcrackerx.com

Founded Year

2018

Stage

Series C | Alive

Total Raised

$241.46M

Last Raised

$167M | 1 yr ago

About Nutcracker Therapeutics

Nutcracker Therapeutics is bringing the combined power of high-technology engineering and advanced biosynthesis to RNA therapeutics through its push-button mRNA synthesis and formulation platform. The company aims to advance mRNA therapeutics into the clinic and engage in strategic partnerships with clinical institutions and pharmaceutical/biotech companies. Its GMP-in-a-box approach to manufacturing is expected to offer significant cost, cycle time, capacity, and point-of-care execution advantages over other RNA manufacturing approaches. Supporting the initial focus on mRNA therapeutics for oncology, the platform will ultimately enable the development and manufacturing of all RNA therapeutics to benefit patients worldwide.

Nutcracker Therapeutics Headquarters Location

5858 Horton Street Suite 540

Emeryville, California, 94608,

United States

510-473-8478

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Nutcracker Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Nutcracker Therapeutics in 1 CB Insights research brief, most recently on Feb 3, 2021.

Expert Collections containing Nutcracker Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Nutcracker Therapeutics is included in 2 Expert Collections, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Nutcracker Therapeutics Patents

Nutcracker Therapeutics has filed 7 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • Fluid dynamics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/14/2021

9/20/2022

Molecular biology, Biotechnology, Genetics, Molecular genetics, Membrane biology

Grant

Application Date

6/14/2021

Grant Date

9/20/2022

Title

Related Topics

Molecular biology, Biotechnology, Genetics, Molecular genetics, Membrane biology

Status

Grant

Latest Nutcracker Therapeutics News

Dr. Rob Schott Joins Nutcracker Therapeutics as Chief Medical Officer

Sep 12, 2022

Dr. Schott will oversee the advancement of Nutcracker Therapeutics’ oncology pipeline, helping to expand the company’s novel RNA therapeutics platform The announcement follows several recent C-suite hires, adding significant pharmaceutical industry and drug development experience to Nutcracker Therapeutics’ executive team September 12, 2022 08:00 AM Eastern Daylight Time EMERYVILLE, Calif.--( BUSINESS WIRE )-- Nutcracker Therapeutics, Inc. , a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today appointed Rob Schott, M.D., M.P.H, F.A.C.C., as Chief Medical Officer. Dr. Schott joins Nutcracker Therapeutics ahead of planned major clinical milestones for its lead program, NTX-0250, and will guide the clinical advancement of the company’s oncology pipeline. “Rob’s extensive background, which includes driving successful clinical development programs within the pharmaceutical and biotechnology industries, gives us full confidence in his ability to oversee the continuous evolution of our pipeline,” said Igor Khandros, Ph.D., cofounder and Chief Executive Officer of Nutcracker Therapeutics. “The biological versatility of RNA equips Nutcracker Therapeutics with the tools to reimagine the treatment landscape of oncology, and beyond,” explained Khandros. “Dr. Schott’s robust track record adds a new dimension of invaluable industry know-how to a team of talented individuals working to bring transformative RNA therapies to patients.” Dr. Schott comes to Nutcracker Therapeutics from Sangamo Therapeutics, where he held the position of Senior Vice President and Head of Development, spearheading clinical strategy across numerous programs. Prior to Sangamo, Dr. Schott served as Chief Medical Officer at Chorus, an operationally independent subsidiary of Eli Lilly and Company, focused on expanding the latter’s pipeline via early-phase candidate selection and discovery. While at Chorus, Dr. Schott led the implementation of innovative processes designed to achieve clinical proof-of-concept more efficiently for early-stage drug candidates. Dr. Schott’s earlier career as a practicing cardiologist led to his role at Sacramento’s Sutter Medical Center as Cardiovascular Department Chair and Vice President of Medical Affairs. He attended the University of Michigan, where he earned his undergraduate and medical degrees. He then worked as a postdoctoral fellow at the Harvard Medical School before training in cardiovascular medicine at Massachusetts General Hospital. “I see RNA as a drug modality with enormous potential, so I immediately connected with Nutcracker Therapeutics’ distinct methodology of RNA drug development,” commented Dr. Schott. “The unique ability of the company’s technology platform to rapidly design and interrogate RNA molecules will be key to realizing the therapeutic potential of this drug class within oncology and beyond. I look to utilize my clinical expertise to advance Nutcracker Therapeutics’ pipeline and contribute to a culture built on dedication to improving patient lives.” Dr. Schott’s appointment arrives on the heels of several other recent additions , bolstering a tested leadership core, including John Stubenrauch, Ph.D., as Chief Operating Officer, who had served as Vice President of Biologics Commercial Operations at Gilead Sciences. Drs. Schott and Stubenrauch join the company after the unveiling of Nutcracker Therapeutics’ oncology pipeline in June, comprising three mRNA candidates targeting HPV-driven tumors, T-cell lymphoma, and genitourinary tumors. About Nutcracker Therapeutics, Inc. Nutcracker Therapeutics, Inc. is an RNA therapeutics company that has combined the power of advanced engineering with high-precision biosynthesis to deploy a complete RNA platform that encompasses the design, delivery, and manufacturing of RNA medicines. Armed with this high-tech advantage, the company has initiated multiple therapeutic programs with the support of clinical investigators at leading institutions. Nutcracker Therapeutics’ technology platform has the potential to significantly reduce costs and cycle times for RNA therapeutic development, with dramatic advantages in speed and capacity scaling over other RNA manufacturing approaches. For more information, visit www.nutcrackerx.com . Contacts

Nutcracker Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Nutcracker Therapeutics Rank

  • When was Nutcracker Therapeutics founded?

    Nutcracker Therapeutics was founded in 2018.

  • Where is Nutcracker Therapeutics's headquarters?

    Nutcracker Therapeutics's headquarters is located at 5858 Horton Street, Emeryville.

  • What is Nutcracker Therapeutics's latest funding round?

    Nutcracker Therapeutics's latest funding round is Series C.

  • How much did Nutcracker Therapeutics raise?

    Nutcracker Therapeutics raised a total of $241.46M.

  • Who are the investors of Nutcracker Therapeutics?

    Investors of Nutcracker Therapeutics include ARCH Venture Partners, Bluebird Ventures and Bill & Melinda Gates Foundation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.